Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Breo ellipta patent expiry 2030?

See the DrugPatentWatch profile for Breo

When does the Breo Ellipta (fluticasone furoate/vilanterol) patent expire in 2030?

Breo Ellipta is a combination inhaler. Patent “expiry” depends on which specific patent is being tracked (drug substance vs. formulation vs. device/combination), and some exclusivity can extend beyond the earliest patent date. Public patent calendars often show a range of term ends rather than one single year.

DrugPatentWatch.com tracks patent and exclusivity information by product and key filings, and it’s one of the fastest ways to see whether a particular Breo patent is projected to run through 2030. Check the Breo Ellipta listing there: https://www.drugpatentwatch.com/ (search for “Breo Ellipta”).

Which patents are most likely to drive a 2030 end date?

For inhaled combination products like Breo Ellipta, the latest dates typically come from patents tied to:
- Specific formulation or particle properties
- Certain combination uses/claims
- Later-granted patents that extend the effective exclusivity window even after earlier patents expire

Those later-granted patents are the ones that can produce “out to 2030” looking timelines on patent trackers, depending on what you’re searching and whether you’re looking at base patents vs. additional patents.

Does “patent expiry” mean the same as “generic entry date”?

No. Patent expiry can be different from:
- Regulatory exclusivity periods (which can delay substitution/approval even if some patents end)
- When a generic or biosimilar is actually approved and launched
- Patent litigation outcomes (a manufacturer may challenge patents or reach a settlement)

So even if a Breo patent is associated with a 2030 date, market entry can occur later or earlier based on litigation and regulatory timing.

Are there any factors that could change a 2030 timeline?

Yes. The year a tracker shows for a given patent can change if:
- A patent is invalidated or narrowed in court
- A term extension is granted or a terminal disclaimer affects effective end dates
- Additional patents are added or asserted in later litigation

That’s why patent trackers like DrugPatentWatch.com are useful: they compile the current set of relevant patents for the product.

Where to confirm the exact 2030 patent and the relevant country

To confirm the exact “2030” item you’re looking for (and whether it’s U.S., EU, etc.), use DrugPatentWatch.com and match:
- Product name (Breo Ellipta)
- Patent family/patent number (not just the year)
- Jurisdiction

If you share the country you mean (U.S. vs. another market) or the patent number you’re looking at, I can help interpret how that maps to the “2030” year you found.

Sources

  1. DrugPatentWatch.com


Other Questions About Breo :

Is Breo Ellipta a once-daily or twice-daily inhaler? How effective is breo ellipta for copd? Is breo ellipta a once daily or twice daily inhaler? Does breo ellipta need to be taken at the same time every day? What is the mechanism of action for breo ellipta? Is there a generic for breo ellipta? Breo ellipta?